Neil H. Baum, MD, and E. David Crawford, MD, presented “Interviews with Legends – Urology Education and the Future of PCa Screening, Detection, and Management” for the Grand Rounds in Urology audience in February 2023.

How to cite: Baum, Neil H. MD, and Crawford, E. David, MD. “Interviews with Legends – Urology Education and the Future of PCa Screening, Detection, and Management” February 2023. Accessed Mar 2023. https://grandroundsinurology.com/interviews-with-legends-urology-education-and-the-future-of-pca-screening-detection-and-management/

Interviews with Legends – Urology Education and the Future of PCa Screening, Detection, and Management

In his latest Interviews with Legends feature, Grand Rounds in Urology (GRU) Contributing Editor Neil H. Baum, MD, sits down with Editor-in-Chief E. David Crawford, MD, to discuss the educational mission of GRU, Dr. Crawford’s contribution to prostate cancer screening, detection, and treatment, as well as what the future holds for early detection and treatment. The two discuss the origins of GRU as a print publication, and how it has evolved into a video-driven educational site featuring original presentations on a range of urology topics, as well as presentations from cutting-edge CME conferences in urology and uro-oncology. Next, Dr. Baum asks Dr. Crawford about how he developed his PSA screening cutoff of 1.5 ng/ml, and how it has enabled physicians to detect a broader range of cancers before they can metastasize. Dr. Crawford asserts that there should be no hard life expectancy cutoff for giving men options to deal with their prostate cancer–Even with life expectancy of 5-6 years, localized treatment can improve quality of life and prevent other urologic disorders associated with prostate cancer, including urinary problems and enlarged prostate. Last, the two discuss what’s next in the field of prostate cancer treatment. Dr. Crawford believes that prostate cancer will have an entirely different treatment algorithm in 5 years, as physicians integrate advances in PET scanning to further localize disease, and the requirements for biopsy change.

E. David Crawford, MD
University of California San Diego
La Jolla, California